配售所得款项总额预期约6235万港元，所得款项净额则约5934万港元。公司拟将认购事项所得款项净额 按下列方式动用：(i)40%用于TST001及TST002等管线资产的临床开发;(ii)30%用于推进最具前景且具有 近期对外许可潜力的临床前阶段管线资产，包括TST801、TST013及TST786等;(iii)30%将用于营运资金 及一般用途，从而提高公司的财务稳健性，包括但不限于一般业务运营及业务发展等。 智通财经APP讯，创胜集团-B(06628)发布公告，于2025年9月10日，公司拟配售1440万股股份，占于完 成配售后经扩大已发行股份(不包括库存股份)总数约3.20%。配售价为每股配售股份4.33港元，较9月9日 收市价每股5.33港元折让约18.76%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致之任何損失承擔任何責任 本公告或其任何副本皆不得在美國或在發放或分派本公告可能違法的任何其他司法權區境內直 接或間接發放或分派。 本公告僅供參考，不構成收購、購買或認購本公司任何證券的邀請或要約。 本公告並非在美國購買或認購任何證券之要約或招攬，亦不構成其一部分。本公告所述證券並 未且將不會根據《1933年美國證券法》（「美國證券法」）登記，亦不會在美國提呈或出售，除非 根據美國證券法作出登記或獲豁免或為毋須根據美國證券法作出登記之交易。本公司無意根據 美國證券法登記本公告內所指之任何證券，或在美國進行證券之公開發售。 Transcenta Holding Limited 創勝集團醫藥有限公司 （以存續方式於開曼群島註冊的有限公司） （股份代號：6628） 根據一般授權配售新股 獨家整體協調人、獨家全球協調人兼獨家配售代理 中銀國際亞洲有限公司 1 董事會宣佈，於2025年9月10日（交易時段前），本公司及配售代理訂立配售協 議， ...

致：香港交易及結算所有限公司 公司名稱: 創勝集團醫藥有限公司（以存續方式於開曼群島註冊的有限公司） 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 本月底法定/註冊股本總額： USD 1,000,000 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06628 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 434,897,445 | | 2,516,500 | | 437,413,945 | | 增加 / 減少 (-) | | | 62,000 | | 0 | | ...

Group 1 - The Hang Seng Index fell by 0.4%, while the Hang Seng Tech Index decreased by 0.54%, with a total turnover of 152 billion HKD in the Hong Kong stock market during the morning session [1] - The Hang Seng Biotechnology Index rose by 1%, with notable gains from companies such as MicroPort Scientific Corporation (02252) up by 10%, and Four Seasons Medicine (00460) up by 8% [1] Group 2 - MicroPort Scientific Corporation (02252) saw a rise of over 10%, indicating renewed interest in the robotics industry and steady progress in the company's commercialization efforts [2] - Dongyang Sunshine Pharmaceutical (06887) increased by nearly 7%, reporting a mid-term gross profit of 1.468 billion HKD, with key data on Ifenprodil presented at the US IPF summit [2] - Chuangsheng Group-B (06628) surged over 28%, with a mid-term net loss narrowing by 17.9%, and TST001 research data making its debut at ASCO [2] - Kingsoft Holdings (03918) rose by over 6%, with first-half performance exceeding market expectations, although uncertainties remain regarding the Naga3 project according to Citigroup [2] - Green Power Environmental (01330) increased by over 7%, with a 24.49% year-on-year increase in net profit attributable to shareholders, driven by its gas supply business [2] - Hylink Technology (01860) rose by 7.9%, with first-half revenue increasing by 40% year-on-year, and institutions optimistic about the continued release of the Mintegral platform's flywheel effect [2] - Zhi Zi Cheng Technology (09911) rose by over 6%, with first-half net profit nearly doubling, and the group's gross profit margin expected to improve significantly year-on-year [2] - Four Seasons Medicine (00460) rose by over 7%, achieving profitability in the first half and making substantial progress in its AI + medical beauty strategic layout [2] - Guofu Quantum (00290) increased by 6.86%, with a cumulative increase of nearly 1.8 times this year, collaborating with Huajian Medical to advance RWA ecosystem construction [2] - New Idea Network Group (01686) fell by over 17% post-results, with annual net profit increasing by 8% to 979 million HKD [2]

Core Viewpoint - Chuangsheng Group-B (06628) experienced a significant intraday surge of over 28%, reaching a price of 4.9 HKD, with a trading volume of 21.44 million HKD. The company reported a 40.6% year-on-year decline in revenue to 2.711 million HKD for the mid-year 2025, while the loss narrowed by 17.9% to approximately 110 million HKD, resulting in a loss per share of 0.27 HKD. The revenue decline was primarily attributed to a reduction in CDMO services [1][2]. Group 1 - Chuangsheng Group-B's mid-year 2025 revenue was 2.711 million HKD, a decrease of 40.6% year-on-year [1] - The company reported a loss of approximately 110 million HKD, which is a 17.9% improvement compared to the previous year [1] - The loss per share for the period was 0.27 HKD [1] Group 2 - Recent breakthroughs in research and clinical trials were highlighted, particularly the TST001 treatment for gastric cancer, which showed a median overall survival (mOS) of 20.4 months in a study involving 82 patients [1] - In a subgroup of 26 patients with high CLDN18.2 expression, the mOS was 21.7 months, with a median progression-free survival (mPFS) of 16.6 months and a confirmed objective response rate (cORR) of 68% [1] - The company is set to initiate a global Phase III clinical trial for TST001 targeting gastric and gastroesophageal cancers following regulatory approval [2] Group 3 - The osteoporosis drug Blosozumab (TST002) has entered Phase II clinical trials in China, yielding positive early results [2] - The company has also made early clinical progress with innovative ADC and bispecific antibody drugs targeting tumors and autoimmune diseases [2]

Core Viewpoint - Chuangsheng Group-B (06628) experienced a significant stock price increase of 28.27%, reaching HKD 4.9, with a trading volume of HKD 21.44 million, following the announcement of its 2025 interim results which showed a revenue decline of 40.6% year-on-year [1] Financial Performance - The company reported a revenue of HKD 2.711 million for the 2025 interim period, a decrease of 40.6% compared to the previous year [1] - The net loss for the period was approximately HKD 110 million, which represents a 17.9% reduction year-on-year [1] - Earnings per share (EPS) showed a loss of HKD 0.27 [1] Clinical Developments - Chuangsheng Group has made significant breakthroughs in research and clinical trials, particularly with TST001 in combination with PD1/CAPOX for first-line treatment of gastric cancer, achieving a median overall survival (mOS) of 20.4 months among 82 enrolled patients [1] - In a subgroup of 26 patients with high expression of CLDN18.2, the mOS was 21.7 months, with a median progression-free survival (mPFS) of 16.6 months and a confirmed objective response rate (cORR) of 68%, with a median duration of response (mDoR) of 16.5 months [1] Future Clinical Trials - Following recent performance meetings, the company plans to initiate a global Phase III clinical trial for TST001 targeting gastric and gastroesophageal cancers upon receiving regulatory approval [2] - The osteoporosis drug Blosozumab (TST002) has entered Phase II clinical trials in China, showing positive early results [2] - The company is also advancing early clinical progress on innovative ADC and bispecific antibody drugs targeting tumors and autoimmune diseases [2]

Group 1 - The company reported a revenue of 2.711 million, representing a year-on-year decrease of 40.6% [1] - The company incurred a loss of approximately 110 million, which is a year-on-year narrowing of 17.9% [1] - The loss per share was 0.27 yuan [1] Group 2 - The decrease in revenue was primarily attributed to a reduction in CDMO services [1]

Core Viewpoint - The company reported a significant decline in revenue and a narrowed loss for the mid-year results of 2025, primarily due to a decrease in CDMO services [1] Financial Performance - Revenue for the period was 2.711 million, representing a year-on-year decrease of 40.6% [1] - The company incurred a loss of approximately 110 million, which is a 17.9% improvement compared to the previous year [1] - Earnings per share were reported at a loss of 0.27 [1] Operational Insights - The decrease in revenue is attributed mainly to a reduction in CDMO (Contract Development and Manufacturing Organization) services [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Transcenta Holding Limited 創勝集團醫藥有限公司 （以存續方式於開曼群島註冊的有限公司） （股份代號：6628） (1) 截至2025年6月30日止六個月的中期業績公告；及 (2) 變更所得款項用途 創勝集團醫藥有限公司（「本公司」）董事（「董事」）會（「董事會」）欣然公佈本公司 及其附屬公司（統稱「本集團」）截至2025年6月30日止六個月（「報告期間」）的未經 審核綜合業績，及與2024年同期經營業績的比較。該等業績乃基於報告期間的未 經審核綜合中期財務報表，而有關報表乃根據國際財務報告準則會計準則（「國際 財務報告準則」）而編製並已由本公司審計委員會（「審計委員會」）及本公司核數師 德勤•關黃陳方會計師行審閱。 於本公告內，「我們」及「我們的」指本公司（定義見上文）及倘文義另有所指，則 指本集團（定義見上文）。本公告所載若干金額及百分比數字已經約整，或約整至 小數點後一位 ...

Group 1 - The biotechnology sector in the Hong Kong stock market experienced a significant decline, with several companies reporting substantial drops in their stock prices [1] - Notable declines include Clover Biopharmaceuticals, which fell by 14.13%, and Beigene, which dropped by 8.33% [2] - Other companies such as Innovent Biologics and WuXi Biologics also saw declines exceeding 5%, indicating a broader trend of negative performance in the sector [1][2] Group 2 - The following companies reported specific percentage declines: Clover Biopharmaceuticals (-14.13%), Beigene (-8.33%), and Innovent Biologics (-6.50%) [2] - Additional companies with notable declines include Kintor Pharmaceutical (-6.38%), CanSino Biologics (-5.98%), and Zai Lab (-5.50%) [2] - The overall trend suggests a challenging environment for biotechnology stocks in the Hong Kong market [1]